An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/20/2018 |
| Start Date: | February 9, 2017 |
| End Date: | February 21, 2021 |
Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
The purpose of this study is to evaluate safety and efficacy of different administration
regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Advanced Renal Cell Carcinoma
- Must have full activity or, if limited, must be able to walk and carry out light
activities such as light house work or office work
- Must have at least 1 lesion with measurable disease
Exclusion Criteria:
- Subjects with active central nervous system metastases
- Subjects who received prior therapy with checkpoint inhibitor
- Subjects with active, known or suspected autoimmune disease
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
5
sites
Click here to add this to my saved trials
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials